Compare ANAB & MMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ANAB | MMI |
|---|---|---|
| Founded | 2005 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 2017 | 2013 |
| Metric | ANAB | MMI |
|---|---|---|
| Price | $49.61 | $27.59 |
| Analyst Decision | Buy | Sell |
| Analyst Count | 11 | 2 |
| Target Price | ★ $59.90 | $29.00 |
| AVG Volume (30 Days) | ★ 503.4K | 448.3K |
| Earning Date | 11-04-2025 | 11-07-2025 |
| Dividend Yield | N/A | ★ 1.78% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $169,467,000.00 | ★ $751,284,000.00 |
| Revenue This Year | $135.45 | $11.94 |
| Revenue Next Year | N/A | $15.59 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 196.42 | 20.74 |
| 52 Week Low | $12.21 | $27.35 |
| 52 Week High | $48.44 | $41.94 |
| Indicator | ANAB | MMI |
|---|---|---|
| Relative Strength Index (RSI) | 76.34 | 37.90 |
| Support Level | $43.92 | $27.38 |
| Resistance Level | $47.86 | $28.26 |
| Average True Range (ATR) | 2.36 | 0.82 |
| MACD | 0.19 | -0.07 |
| Stochastic Oscillator | 95.95 | 9.87 |
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
Marcus & Millichap Inc is a national brokerage firm specializing in commercial real estate investment sales, financing, research, and advisory services. The company offers three primary services to its clients: commercial real estate investment brokerage, financing, and ancillary services, including other research, advisory, and consulting services. The company generates revenues by collecting fees on the sale and financing of commercial properties. These fees consist of commissions collected upon the sale of a property and fees collected from the placement of loans.